Mydecine Innovations Group Archives

Psychedelics News

Mydecine Innovations Group

Don’t Miss

9 May 2022

News You Might Have Missed: May 9th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic industry news to help you catch up and stay informed....

By Microdose NewsDesk

Finance

15 Apr 2022

Mydecine Announces Reverse Stock-Split

Mydecine announced an upcoming reverse stock-split....

By Jason Najum

Finance

1 Apr 2022

Mydecine Releases 2021 Financials and Announces Capital Raise

We're combining two announcements here....

By Microdose

Industry

24 Mar 2022

Mydecine Receives IRB Approval for Phase 2b Smoking Trial

Today the company reported the IRB (Institutional Review Board) has approved its Phase 2b study, paving the way for the next major step (FDA approval of its IND or Investigational...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

20 Dec 2021

Company Update: A Look at Mydecine Innovations Group

With the recent news of Mydecine securing capital for their upcoming trials, the company might finally be ready to make that next jump....

By Microdose

Industry

9 Dec 2021

Mydecine Secures Financing and Provides Company Update

Mydecine Secures Financing and Provides Company Update....

By Jason Najum

Press Releases

16 Mar 2021

Mydecine Innovations Group Provides Update on European Operations

DENVER, March 16, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the...

By Microdose

Press Releases

10 Mar 2021

Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Assets

*NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES DENVER, March 10, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE:...

By Microdose

Press Releases

9 Mar 2021

Microdose Launches Special Report Spotlighting Intellectual Property & Patents in Psychedelic Drug Development

By Microdose

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result